Retrophin Company Profile (NASDAQ:RTRX)

Retrophin trades on the NASDAQ under the ticker symbol "RTRX."

Retrophin, Inc. (NASDAQ:RTRX) issued its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.24) by $0.10. The firm had revenue of $38.80 million for the quarter, compared to the consensus estimate of $37.36 million. Retrophin had a negative net margin of 48.74% and a negative return on equity of 7.31%. The business's revenue was up 16.5% on a year-over-year basis. During the same period last year, the company posted $0.07 earnings per share. View Retrophin's Earnings History.

3 brokers have issued 12 month price objectives for Retrophin's stock. Their forecasts range from $28.00 to $45.00. On average, they expect Retrophin's stock price to reach $36.50 in the next year. View Analyst Ratings for Retrophin.

Here are some recent quotes from research analysts about Retrophin stock:

• 1. According to Zacks Investment Research, "Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company's approved products include Chenodal®, Cholbam, and Thiola®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis, pantothenate kinase-associated neurodegeneration, infantile spasms, nephrotic syndrome and others. Retrophin, Inc. is based in San Diego. " (5/3/2017)
• 2. BMO Capital Markets analysts commented, "We maintain our Outperform rating on RTRX shares following Retrophin's announcement to initiate a Phase III trial in 2H17 for Sparsentan. Our price target decreases to $45 from $46, as we push back Sparsentan estimates by two years, but increase our probability of success to 75% from 55%. We believe FDA agreement for proteinuria as an approvable endpoint removes significant uncertainty around Sparsentan's regulatory path as well as avoids a lengthy trial requiring eGFR or kidney survival as endpoints. We estimate Sparsentan peak sales (US only) of $1bn." (3/2/2017)

Some companies that are related to Retrophin include Radius Health (RDUS), MyoKardia (MYOK), Acceleron Pharma (XLRN), Lexicon Pharmaceuticals (LXRX), Clinigen Group PLC (CLIN), Sangamo Therapeutics (SGMO), Dynavax Technologies Corporation (DVAX), Dermira (DERM), Acorda Therapeutics (ACOR), Epizyme (EPZM), Xencor (XNCR), NeuroDerm (NDRM), Athenex (ATNX), Five Prime Therapeutics (FPRX), Ascendis Pharma A/S (ASND), Omeros Corporation (OMER), Amarin Corporation PLC (AMRN) and ZIOPHARM Oncology (ZIOP).

Retrophin's management team includes the folowing people:

• Gary A. Lyons, Independent Chairman of the Board
• Stephen J. Aselage, President, Chief Executive Officer, Director
• Laura M. Clague CPA, Chief Financial Officer, Senior Vice President
• Neil McFarlane, Chief Operating Officer
• Elizabeth E. Reed, Senior Vice President, General Counsel and Corporate Secretary
• William E. Rote Ph.D., Senior Vice President and Head of Research and Development
• Roy D. Baynes M.D. Ph.D., Independent Director
• Timothy P. Coughlin CPA, Independent Director
• John W. Kozarich, Independent Director
• Jeffrey A. Meckler, Independent Director

Retrophin's stock is owned by many different of retail and institutional investors. Top institutional investors include Broadfin Capital LLC (7.46%), FMR LLC (4.98%), Jennison Associates LLC (4.45%), Vanguard Group Inc. (4.28%), Macquarie Group Ltd. (3.10%) and State Street Corp (3.10%). Company insiders that own Retrophin stock include Alvin Shih, Jeffrey A Meckler, Jensen Margaret E Valeur, Neil F Mcfarlane and Steve Aselage. View Institutional Ownership Trends for Retrophin.

Retrophin's stock was sold by a variety of institutional investors in the last quarter, including Senzar Asset Management LLC, Numeric Investors LLC, Jennison Associates LLC, FMR LLC, OxFORD Asset Management LLP, Broadfin Capital LLC, Tudor Investment Corp ET AL and State Street Corp. Company insiders that have sold Retrophin stock in the last year include Neil F Mcfarlane and Steve Aselage. View Insider Buying and Selling for Retrophin.

Retrophin's stock was acquired by a variety of institutional investors in the last quarter, including Oak Ridge Investments LLC, Dimensional Fund Advisors LP, Macquarie Group Ltd., Vanguard Group Inc., PDT Partners LLC, Emory University, Schwab Charles Investment Management Inc. and Alliancebernstein L.P.. View Insider Buying and Selling for Retrophin.

Shares of Retrophin can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Retrophin stock can currently be purchased for approximately $22.63.